XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2023
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:
 
Three Months Ended June 30,Six Months Ended June 30,
(in thousands)2023202220232022
Included in research and development expense$297 $126 $691 $460 
Included in selling, general and administrative expense1,284 929 1,954 1,747 
Total stock-based compensation expense$1,581 $1,055 $2,645 $2,207 
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards
The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
 
Six Months Ended June 30,
20232022
Risk-free interest rate3.61 %1.87 %
Dividend yield%%
Expected volatility of Cardiff Oncology common stock109 %106 %
Expected term(1)
5.3 years6.0 years
(1)The expected term for options granted after January 1, 2023 is estimated based on the Company's historical employee data. Prior to January 1, 2023, the Company used the "simplified method" to estimate expected term.
Summary of Stock Option Activity and of Changes in Stock Options Outstanding
A summary of stock option activity and changes in stock options outstanding is presented below:
 
Total OptionsWeighted-Average
Exercise Price
Per Share
Intrinsic
Value
Balance outstanding, December 31, 20225,069,458 $5.92 $19,322 
Granted2,088,608 $1.71  
Forfeited and expired(554,405)$7.12  
Balance outstanding, June 30, 20236,603,661 $4.49 $23,351 
Exercisable at June 30, 20232,766,027 $6.16 $21,713 
Vested and expected to vest at June 30, 20236,410,335 $4.55 $23,269 
Summary of Warrant Activity and Changes in Warrants Outstanding
A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
 
Total WarrantsWeighted-Average
Exercise Price
Per Share
Weighted-Average
Remaining Contractual
Term
Balance outstanding, December 31, 20224,360,968 $5.33 2.1 years
Expired(1,553,020)$10.54  
Balance outstanding, June 30, 20232,807,948 $2.45 2.5 years
Schedule of Preferred Stock
A summary of our Company's classes of preferred stock is presented below:
Shares outstanding
ClassPar valueShares designatedAs of June 30,
2023
As of December 31,
2022
Series A Convertible Preferred Stock$0.001 277,100 60,600 60,600 
Series B Convertible Preferred Stock$0.001 8,860 — — 
Series C Convertible Preferred Stock$0.001 200,000 — — 
Series D Convertible Preferred Stock$0.0001 154,670 — — 
Series E Convertible Preferred Stock$0.001 865,824 — — 

Subsequent to quarter-end the Company filed a certificate of elimination and the Series B, C, D & E preferred stock have been eliminated from authorized series of preferred stock.